Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L C Ong

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
Journal of Paediatrics and Child Health|October 1, 1996
Comparison of morbidities in very low birthweight and normal birthweight infants during the first year of life in a developing countryN Y Boo, L C Ong, M S Lye, et al.
Annals of Tropical Paediatrics|January 13, 1998
Relationship between head growth and neurodevelopmental outcome of Malaysian very low birthweight infants during the 1st year of lifeL C Ong, N Y Boo, V Chandran, et al.
HIV Medicine|September 25, 2012
HIV-associated fatigue in the era of highly active antiretroviral therapy: novel biological mechanisms?B A I Payne, C L Hateley, E L C Ong, et al.
Singapore Medical Journal|March 1, 1997
Neurodevelopmental outcome of Malaysian very low birth weight infants: predictive value of cranial ultrasound appearancesL C Ong, N Y Boo, V Chandran, et al.
Blood Cancer Journal|July 26, 2012
The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AMLV Novotny-Diermayr, S Hart, K C Goh, et al.
Medical Sciences (Basel, Switzerland)|November 2, 2018
Pyogenic Spondylodiscitis: Risk Factors for Adverse Clinical Outcome in Routine Clinical PracticeJohn D Widdrington, Ingrid Emmerson, Milo Cullinan, et al.
Blood Cancer Journal|July 26, 2012
Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemiaS Hart, K C Goh, V Novotny-Diermayr, et al.
Leukemia|August 24, 2011
TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic propertiesK C Goh, V Novotny-Diermayr, S Hart, et al.
Leukemia|June 22, 2011
SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignanciesS Hart, K C Goh, V Novotny-Diermayr, et al.
Current Cancer Drug Targets|September 17, 2009
Sunitinib (SUTENT, SU11248) suppresses tumor growth and induces apoptosis in xenograft models of human hepatocellular carcinomaH Huynh, V C Ngo, S P Choo, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Journal of Paediatrics and Child Health|October 1, 1996
Comparison of morbidities in very low birthweight and normal birthweight infants during the first year of life in a developing countryN Y Boo, L C Ong, M S Lye, et al.
Annals of Tropical Paediatrics|January 13, 1998
Relationship between head growth and neurodevelopmental outcome of Malaysian very low birthweight infants during the 1st year of lifeL C Ong, N Y Boo, V Chandran, et al.
HIV Medicine|September 25, 2012
HIV-associated fatigue in the era of highly active antiretroviral therapy: novel biological mechanisms?B A I Payne, C L Hateley, E L C Ong, et al.
Singapore Medical Journal|March 1, 1997
Neurodevelopmental outcome of Malaysian very low birth weight infants: predictive value of cranial ultrasound appearancesL C Ong, N Y Boo, V Chandran, et al.
Blood Cancer Journal|July 26, 2012
The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AMLV Novotny-Diermayr, S Hart, K C Goh, et al.
Medical Sciences (Basel, Switzerland)|November 2, 2018
Pyogenic Spondylodiscitis: Risk Factors for Adverse Clinical Outcome in Routine Clinical PracticeJohn D Widdrington, Ingrid Emmerson, Milo Cullinan, et al.
Blood Cancer Journal|July 26, 2012
Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemiaS Hart, K C Goh, V Novotny-Diermayr, et al.
Leukemia|August 24, 2011
TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic propertiesK C Goh, V Novotny-Diermayr, S Hart, et al.
Leukemia|June 22, 2011
SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignanciesS Hart, K C Goh, V Novotny-Diermayr, et al.
Current Cancer Drug Targets|September 17, 2009
Sunitinib (SUTENT, SU11248) suppresses tumor growth and induces apoptosis in xenograft models of human hepatocellular carcinomaH Huynh, V C Ngo, S P Choo, et al.
Pageof 6